Archives
-
WDR36 Links Glycolysis to Human Trophectoderm Fate
2026-09-22
The reference study identifies WDR36 as a regulator of human blastoid formation and trophectoderm differentiation, connecting this developmental function to glycolytic metabolism and LDHA. Its combination of mouse embryo validation, human blastoid modeling, transcriptomics, targeted metabolomics, and protein-interaction analysis provides a mechanistic framework for studying early developmental arrest.
-
Omeprazole (A2845): Research Protocol Guide
2026-09-22
Omeprazole (A2845) provides a defined H+,K+-ATPase inhibitor for controlled gastric acid secretion research, antiulcer activity studies, and related preclinical workflows. It is intended for scientific research only and should not be used for diagnosis, clinical treatment, or other medical purposes.
-
Omeprazole A2845: Practical Research Protocol
2026-09-21
Omeprazole (SKU A2845) is a research-grade H+,K+-ATPase inhibitor for controlled studies of gastric acid secretion, proton pump inhibition, and antiulcer mechanisms. It is supplied for scientific research only, is insoluble in water and ethanol, and should not be used as a diagnostic, therapeutic, or clinical-grade formulation.
-
Generating Hepatobiliary Organoids from Human iPSCs
2026-09-21
Wu and colleagues developed a three-stage, cell-free system for producing hepatobiliary organoids from human induced pluripotent stem cells. The model reproduced complementary hepatocyte and biliary functions, offering a useful platform for liver development studies, drug evaluation, and research into regenerative applications.
-
Jasplakinolide Actin Polymerization Workflows
2026-09-20
Jasplakinolide combines membrane access with high-affinity F-actin binding, making it useful for controlled perturbation of filament assembly, organization, and stability. This practical guide covers live-cell assays, fixed-cell imaging, chemical-genetic thinking, and troubleshooting for cytoskeletal, antiproliferative, and antifungal workflows.
-
CFDA-SE for Division-Resolved Cell Tracking
2026-09-19
CFDA-SE enables viable-cell labeling and flow cytometry proliferation tracking through esterase activation, intracellular amine coupling, and generation-by-generation fluorescence dilution. This guide explains how to design robust assays and use division data alongside surfaceome and migration studies without confusing proliferation with cell movement.
-
MDockPeP2_VS for Peptide Inhibitor Discovery
2026-09-18
The 2024 PNAS Nexus study introduces MDockPeP2_VS, a structure-based method that combines molecular docking with conservation between protein folding and protein–peptide binding to make large-scale peptide screening more practical. Applied to TEM-1 β-lactamase, the workflow identified TF7 as an active inhibitor with a reported Ki of 1.37 ± 0.37 μM, providing a computational starting point for β-lactam antibiotic resistance research.
-
Heterologous Regulators and A40926 Production
2026-09-18
The 2024 study shows that StrR-like regulators from distant lipodepsipeptide biosynthetic gene clusters can improve production of teicoplanin and A40926 in heterologous actinobacterial hosts. Its central implication is that regulator function may be portable across pathway boundaries, although the contrasting behavior of Ramo5 and Chers28 demonstrates that cross-pathway activation is selective rather than universal.
-
Thymoquinone Protects Against Doxorubicin Cardiotoxicity
2026-09-17
A 2025 mouse study reports that thymoquinone reduces doxorubicin-associated cardiac injury while restoring antioxidant and ferroptosis-related responses. The work connects functional cardiac measurements with redox biomarkers, pathway proteins, immunohistochemistry, and mitochondrial ultrastructure, providing a useful preclinical framework for studying chemotherapy-induced cardiotoxicity.
-
MDL 28170: A Practical Calpain Inhibitor Workflow
2026-09-17
MDL 28170 combines cell permeability, brain access, and nanomolar calpain and cathepsin B inhibition for mechanistic neuroprotection research. This workflow translates evidence from maternal-surgery models into practical target-engagement, apoptosis assay, ischemia-reperfusion, cardiac, Schwann-cell, and parasite studies.
-
NF 449: Gsα-Selective G Protein Antagonism
2026-09-16
The 1998 PNAS study identified NF 449 and NF 503 as suramin analogues that preferentially inhibit Gsα activation and β-adrenergic receptor–Gs coupling over Gi/Go- and Gq-linked pathways. Its assay strategy established a practical framework for testing subtype-selective G protein antagonism while also clarifying why NF 449 should be interpreted differently in later purinergic receptor studies.
-
Vernakalant Hydrochloride: Rapid AF Conversion
2026-09-16
Vernakalant Hydrochloride, also known as RSD1235, is an atrial-selective antiarrhythmic agent studied for rapid conversion of atrial fibrillation. Its value comes from combined atrial ion-channel modulation, rapid intravenous exposure, and selective prolongation of atrial refractoriness.
-
NIH/3T3 Cells: Recovery, Culture, and QC
2026-09-15
This guide provides a practical recovery, expansion, transfection, viral proliferation, and oncogene research workflow for NIH/3T3 Cells supplied as a cryopreserved mouse fibroblast line. It is intended for controlled laboratory research, not for clinical, diagnostic, or quantitative performance claims beyond the product dossier.
-
SAR131675: Selective VEGFR-3 Inhibitor Guide
2026-09-15
SAR131675 is a selective ATP-competitive VEGFR-3 inhibitor with nanomolar biochemical and cellular activity. It is a useful anti-lymphangiogenic and anti-angiogenic research compound, but its discontinued development and poor solvent compatibility limit translational use.
-
3X (DYKDDDDK) Peptide: Workflow Guide
2026-09-14
Use the 3X (DYKDDDDK) Peptide as a practical competition reagent, detection control, and purification aid for FLAG-tagged constructs. This guide connects routine affinity workflows with membrane-protein structural studies, including the VPS13A–XKR1 mechanism described in a recent cryo-EM study.